homevideos Newshealthcare NewsWockhardt's UTI drug to reduce hospitalisation; NIH to conduct Phase 1 trials: Habil Khorakiwala
Wockhardt's UTI drug to reduce hospitalisation; NIH to conduct Phase-1 trials: Habil Khorakiwala
The National Institute of Allergy and Infectious Diseases (NIAID) in the US is supporting phase-1 clinical trials of a new drug under development. CNBC-TV18 spoke to Habil F Khorakiwala, chairman of Wockhardt to understand more about the drug and trial.
The National Institute of Allergy and Infectious Diseases (NIAID) in the US is supporting phase-1 clinical trials of a new drug under development. CNBC-TV18 spoke to Habil F Khorakiwala, chairman of Wockhardt to understand more about the drug and trial.
Khorakiwala said that this is the first time that NIH will be conducting a phase-1 trial for any company in India.
Talking about the drug, he said that it is expected to reduce hospitalisations and is focused on urinary tract infections (UTIs). “The US FDA has given qualified infectious disease product (QIDP) status which means faster release,” said Khorakiwala.
On business, he said that the company will look at debt reduction of Rs 500 crore via rights issue funds. “The rights issue is Rs 750 crore and we would be managing the debt to the extent of Rs 500 crore of reduction and balance of the money will be used for corporate general purposes,” Khorakiwala said.
For more details, watch the accompanying video
(Edited by : Abhishek Jha)
First Published: Mar 16, 2022 12:06 PM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Phase five Lok Sabha polls: Rae Bareli, Amethi among 14 UP seats going to polls on Monday
May 19, 2024 1:03 PM
AAP protest walk: Arvind Kejriwal challenges BJP to arrest entire party, Delhi Police imposes Section 144
May 19, 2024 12:26 PM
Terror attacks in Kashmir raise concerns ahead of May 20 and May 25 election
May 19, 2024 12:15 PM